Reviva Pharmaceuticals Holdings experienced a significant boost in share prices, soaring by 80% to $6.76. The surge was a direct result of the company's positive topline results and successful completion of its Phase 3 trial. The trial focused on evaluating the efficacy, safety, and tolerability of once-daily brilaroxazine, a serotonin-dopamine signaling modulator, in adults suffering from schizophrenia.

Over the past year, Reviva's stock has demonstrated remarkable growth, increasing by 78%. Although briefly paused due to volatility, it ultimately rebounded, leading to the substantial surge mentioned above.

The Phase 3 trial proved to be a resounding success by achieving its primary endpoint. Brilaroxazine, specifically at a dosage of 50 mg, displayed a statistically significant and clinically meaningful reduction of 10.1 points in the Positive and Negative Syndrome Scale total score in comparison to the placebo at week four.

Furthermore, brilaroxazine demonstrated notable reductions in all major symptom domains and secondary endpoints at week four when compared to the placebo. Even at a lower dosage of 15 mg, brilaroxazine showed promise by outperforming the placebo on the primary endpoint and most secondary endpoints. Furthermore, it achieved statistical significance in two key secondary endpoints.

Looking ahead, Reviva Pharmaceuticals Holdings plans to share long-term data from its trial during the fourth quarter of 2024. Moreover, the company has outlined its intentions to embark on a Phase 3 trial in the first quarter of 2024. If successful, this trial will contribute to Reviva's strategic submission of a new drug application to the FDA, expected in 2025.

HeiQ Reports Widened Pretax Loss for the First Half of the Year

Origin Energy Takeover Proposal Under Scrutiny

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Canadian Investors Increase Holdings of Foreign Securities in June
News

Canadian Investors Increase Holdings of Foreign Securities in June

Canadian investors increased their holdings of foreign securities in June, while foreigners continued to invest in Canad...

Equifax Cuts Outlook for the Year Amid Weak Mortgage Market
News

Equifax Cuts Outlook for the Year Amid Weak Mortgage Market

Equifax Inc. reduces outlook for the year due to weak mortgage market, leading to decline in shares. Revised estimates a...

Else Nutrition Launches Plant-Based Dairy-Alternative Drink for Toddlers in the U.K.
News

Else Nutrition Launches Plant-Based Dairy-Alternative Drink for Toddlers in the U.K.

Leading plant-based dairy alternative company, Else Nutrition, launches toddler drink in the U.K. to tap into the growin...

SoftBank Group Posts Second-Quarter Net Loss
News

SoftBank Group Posts Second-Quarter Net Loss

SoftBank Group reports a net loss of 931.11 billion yen in the second quarter, primarily due to losses from its Vision F...